Ceribell vs Revvity
Side-by-side comparison of AI visibility scores, market position, and capabilities
Ceribell (Nasdaq: CBLL) makes the only FDA-cleared AI point-of-care EEG for seizure detection in all patient ages; reported $89.1M revenue in 2025 (+36% YoY) with 2026 guidance of $111–$115M.
About
Ceribell is a commercial-stage medical technology company that has reimagined the electroencephalogram (EEG) for the acute care setting. Its flagship product is a rapid-application, disposable EEG system with an AI algorithm called Clarity that detects electrographic seizures in real time. The platform is FDA-cleared for use across all patient ages — from pre-term neonates through adults — making it the only point-of-care EEG with that breadth of clearance. In December 2025, Ceribell received additional FDA 510(k) clearance for its AI-powered delirium monitoring solution, the first and only FDA-cleared delirium screening and monitoring device.
Revvity (RVTY) reported ~$2.9B revenue in FY2024. Life science tools and diagnostics company providing instruments, reagents, and software for genomics, newborn screening, and drug discovery. HQ: Waltham, MA.
About
Revvity, Inc. (formerly PerkinElmer) is a global life science tools and diagnostics company, rebranded in 2023 to signal its transformation from a diversified instruments company into a focused provider of solutions for reproductive health, genomics, and applied markets. The company operates in two segments: Life Sciences (analytical instruments, reagents, software for pharmaceutical and academic research) and Diagnostics (immunoassay and molecular diagnostic systems for clinical and screening applications). Revvity is the global leader in newborn screening, processing the tests that check newborns for metabolic and genetic disorders shortly after birth.
Key Details
Capabilities & Ecosystem
Capabilities
Integrations
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.